Inclusion Criteria: Each patient MUST:

- Have histologically confirmed cancer of the colon or rectum with radiologically
documented and measurable metastases (high CEA alone is insufficient for study
entry).

- Have received 3 or fewer regimens in the metastatic setting.

- Not have received prior FOLFIRI or irinotecan in the metastatic setting.

- Have his/her tumor assessed for KRAS status and found to be mutation positive.

- Have NO continuing acute toxic effects (except alopecia) of any prior radiotherapy,
chemotherapy, or surgical procedures, i.e., all such effects must have resolved.

- Have an ECOG Performance Score of 2.

- Have a life expectancy of at least 3 months.

- Have baseline laboratory results as follows:

- Absolute neutrophil count (ANC) 1.5 x 10^9 [SI unit 10^9/L]

- Platelets 100 x10^9 [SI units 10^9/L] (without platelet transfusion)

- Hemoglobin 9.0 g/dL [SI units gm/L] (with or without RBC transfusion)

- Serum creatinine 1.5 x upper limit of normal (ULN)

- Bilirubin ULN

- AST/ALT 2.5 x ULN ( 5 x ULN if with liver metastases)

- Negative pregnancy test for females with childbearing potential.

- Proteinuria < grade 2.

- Have signed an informed consent indicating that the patient is aware of the
neoplastic nature of their disease and have been informed of the procedures of the
protocol, the experimental nature of the therapy, alternatives, potential benefits,
side effects, risks, and discomforts.

- Be willing and able to comply with scheduled visits, the treatment plan, and
laboratory tests.

- Be medically eligible to receive bevacizumab

Exclusion Criteria: No patient may:

- Receive concurrent therapy with any other investigational anticancer agent while on
study.

- Have previously received irinotecan or FOLFIRI in the metastatic setting (patient is
eligible if he/she had received irinotecan or FOLFIRI as adjuvant therapy more than 6
months before entry into the study)

- Have brain metastases.

- Be on immunosuppressive therapy or have known HIV infection or active hepatitis B or
C.

- Have received chemotherapy, radiotherapy, immunotherapy or hormonal therapy or had
surgery (except biopsies) within 28 days prior to receiving the study drug.

- Be a pregnant or breast-feeding woman. Female patients of childbearing potential
must agree to use effective contraception, be surgically sterile, or be
postmenopausal. Male patients must agree to use effective contraception or be
surgically sterile. Barrier methods are a recommended form of contraception.

- Have clinically significant cardiac disease (New York Heart Association, Class III or
IV) including pre-existing arrhythmia, uncontrolled angina pectoris, myocardial
infarction within 1 year prior to study entry, or Grade 2 or higher compromised left
ventricular ejection fraction.

- Have dementia or altered mental status that would prohibit informed consent.

- Have any other acute, or chronic medical or psychiatric condition or laboratory
abnormality that may increase the risk associated with study participation or study
drug administration or may interfere with the interpretation of study results and, in
the judgment of the Principal Investigator, would make the patient inappropriate for
this study.

- Have uncontrolled hypertension, proteinuria, or recent major surgery (all clinical
parameters related to bevacizumab use). Any other clinical parameter considered
important should be discussed with the medical monitor.

Minimum Eligible Age: 18 Years

Maximum Eligible Age: N/A

Eligible Gender: Both